US Stock Market Move | Moderna (MRNA.US) rises more than 7% as data from two new mRNA vaccines show positive results

On Monday, Moderna (MRNA.US) stock price rose, rising more than 7% to $27.85 as of the time of publication. On the news front, Moderna showcased its latest data on mRNA vaccine pipeline at the IDWeek 2025 conference, including clinical results of seasonal flu vaccine mRNA-1010 and combination vaccine mRNA-1018. The data showed that both vaccines were able to induce rapid and strong immune responses in adult participants, with no significant safety concerns observed.